Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen - A subanalysis of the Captopril Prevention Project
L. Niskanen et al., Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen - A subanalysis of the Captopril Prevention Project, DIABET CARE, 24(12), 2001, pp. 2091-2096
OBJECTIVE - The Captopril Prevention Project (CAPPP) evaluated the effects
of an ACE inhibitor-based therapeutic regimen on cardiovascular mortality a
nd morbidity in hypertension. one planned subanalysis of the CAPPP was to e
valuate the outcome in the diabetic patient group.
RESEARCH DESIGN AND METHODS - In the CAPPP, 572 (4.9% of 10,985 hypertensiv
e patients) had diabetes at baseline and were studied according to a prospe
ctive, randomized, open, blinded, end point trial design. Patients aged 25-
66 years with diastolic blood pressure greater than or equal to 100 mmHg we
re included and randomized to receive either captopril or conventional anti
hypertensive treatment (diuretics and/or beta -blockers).
RESULTS - The primary end point, fatal and nonfatal myocardial infarction a
nd stroke as well as other cardiovascular deaths, was markedly lower in the
captopril than in the conventional therapy group (relative risk [RR] = 0.5
9 P = 0.018). Specifically, cardiovascular mortality. defined as fatal stro
ke and myocardial infarction, sudden death, and other cardiovascular death
tended to be lower in the captopril group (RR = 0.48; P = 0.084), and no di
fference was observed between the study groups for stroke (RR = 1.02 P = 0.
96). Myocardial infarctions were less frequent in the captopril group than
in the conventional therapy group (RR = 0.34 P = 0.002). Furthermore, total
mortality was lower in the captopril as compared with the conventional the
rapy group (RR = 0.54; P = 0.034). Patients with impaired metabolic control
seemed to benefit the most from ACE inhibitor-based therapy.
CONCLUSIONS - Captopril is superior to a diuretic/beta -blocker antihyperte
nsive treatment regimen in preventing cardiovascular events in hypertensive
diabetic patients, especially in those with metabolic decompensation.